These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Now that we know what's BeSt, what is good value for the money? Bansback N; Marra CA Arthritis Rheum; 2009 Mar; 61(3):289-90. PubMed ID: 19248126 [No Abstract] [Full Text] [Related]
4. [Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists]. Kulp W; Greiner W; Graf von der Schulenburg JM Pharm Unserer Zeit; 2003; 32(5):420-5. PubMed ID: 14526463 [No Abstract] [Full Text] [Related]
5. Cost-effectiveness analysis: out of touch with clinical reality? Maetzel A Arthritis Rheum; 2005 Feb; 53(1):3-4. PubMed ID: 15696549 [No Abstract] [Full Text] [Related]
6. Rituximab (Rituxan) for rheumatoid arthritis. Med Lett Drugs Ther; 2006 Apr; 48(1233):34-5. PubMed ID: 16625143 [No Abstract] [Full Text] [Related]
7. The economics of treatment in early rheumatoid arthritis. Bansback N; Marra CA; Finckh A; Anis A Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):83-92. PubMed ID: 19233048 [TBL] [Abstract][Full Text] [Related]
11. Back to the future: the managed care approach to rheumatoid arthritis. Sidorov J Manag Care Interface; 2007 Jul; 20(7):28-30. PubMed ID: 17849731 [TBL] [Abstract][Full Text] [Related]
12. PHARMAC responds on TNF inhibitors for inflammatory arthritis. Metcalfe S; Moodie P; Grocott R; Wilkinson T N Z Med J; 2005 Dec; 118(1227):U1799. PubMed ID: 16372039 [No Abstract] [Full Text] [Related]
13. Patient perspectives on cytokine medicines. Bosworth A Cytokine; 2004 Nov 21-Dec 7; 28(4-5):182-5. PubMed ID: 15588694 [No Abstract] [Full Text] [Related]
14. Treatment of rheumatoid arthritis: Tightening the noose. Krug HE J Lab Clin Med; 2001 Jul; 138(1):5-7. PubMed ID: 11433221 [No Abstract] [Full Text] [Related]
15. Infection and rheumatoid arthritis: guilt by association? Albert LJ J Rheumatol; 2000 Mar; 27(3):564-6. PubMed ID: 10743788 [No Abstract] [Full Text] [Related]
16. The pharmacoeconomics of newer therapeutics for rheumatic diseases. Kavanaugh A Rheum Dis Clin North Am; 2006 Feb; 32(1):45-56, viii. PubMed ID: 16504820 [TBL] [Abstract][Full Text] [Related]
17. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis? Kavanaugh A Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716 [No Abstract] [Full Text] [Related]
18. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis. Kavanaugh A; Cohen S; Cush JJ J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347 [No Abstract] [Full Text] [Related]
19. A case study on rheumatoid arthritis. Baker T Am J Manag Care; 2003 Sep; 9(4 Suppl):S87-98. PubMed ID: 14527109 [TBL] [Abstract][Full Text] [Related]